Addax Biosciences is excited to share that our acid-free glyoxal formulation has been used in a recent study, demonstrating superior performance in preserving n...
We are pleased to share another significant step in the entrepreneurial development of Addax Biosciences: Fintech Partners, investment sub-holding controlled by...
We are excited to share another remakable recent study on alternative protocols of tissue fixation that have the potential to revolutionize the interpretation o...
An open label, non-inferiority, multicentric trial proves that Glyoxal Acid-Free (GAF®) histological fixative is a suitable alternative to Formalin. The tri...
We are pleased to share the remarkable outcomes of a recent multi-institutional groundbreaking study: NON-TOXIC ACID-FREE GLYOXAL FIXATIVE FOR VETERINARY HIS...
We are pleased to announce that our GAF® formalin free fixative solution joined the World’s greenest hospital initiative. The fictional city of Grønnköping...
In September 2022 the CEO and founder of Addax Biosciences Professor Bussolati, closed the 34th European Congress of Pathology, with his keynote lecture, entit...